Combination of antibodies specifically recognizing tnfr2 and pd-l1 or pd-1
AssigneeStaidson Biopharma Inc.
InventorsZuoan YI, Wenwu ZHAI, Chong HE
Life of this patent
Estimating the term…
Abstract
The present application provides anti-TNFR2 antibodies, the pharmaceutical composition or combination comprising the anti-TNFR2 antibody and anti-PD-L1 antibody or anti-PD-1 antibody, and methods of using the pharmaceutical composition or the combination with the anti-TNFR2 antibody and anti-PD-L1 antibody or anti-PD-1 antibody to treat cancer or infectious disease.
Claims21
A method of treating cancer or infectious disease in an individual in need thereof, comprising administering to the individual an antibody specifically recognizing human TNFR2 and an antibody specifically recognizing human PD-L1 or PD-1, wherein the anti-TNFR2 antibody comprises:
- a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DDYID (SEQ ID NO:
- 1), an HC-CDR2 comprising EIYPGSGNTYYNEKFKG (SEQ ID NO:
- 2), and an HC-CDR3 comprising SQVYGKIAMDH (SEQ ID NO:
- 3);
- and a light chain variable domain (VL) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASESVDNSGNSFMH (SEQ ID NO:
- 4), a LC-CDR2 comprising RASNLES (SEQ ID NO:
- 5), and a LC-CDR3 comprising QQSKEDPYT (SEQ ID NO:
- 6).
2-3. (canceled)
A pharmaceutical composition comprising an antibody specifically recognizing human TNFR2 and an antibody specifically recognizing human PD-L1 or PD-1, wherein the anti-TNFR2 antibody comprises:
- a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DDYID (SEQ ID NO:
- 1), an HC-CDR2 comprising EIYPGSGNTYYNEKFKG (SEQ ID NO:
- 2), and an HC-CDR3 comprising SQVYGKIAMDH (SEQ ID NO:
- 3);
- and a light chain variable domain (VL) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASESVDNSGNSFMH (SEQ ID NO:
- 4), a LC-CDR2 comprising RASNLES (SEQ ID NO:
- 5), and a LC-CDR3 comprising QQSKEDPYT (SEQ ID NO:
- 6).
A combination of an antibody specifically recognizing human TNFR2 and an antibody specifically recognizing human PD-L1 or PD-1, wherein the anti-TNFR2 antibody comprises:
- a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DDYID (SEQ ID NO:
- 1), an HC-CDR2 comprising EIYPGSGNTYYNEKFKG (SEQ ID NO:
- 2), and an HC-CDR3 comprising SQVYGKIAMDH (SEQ ID NO:
- 3);
- and a light chain variable domain (VL) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASESVDNSGNSFMH (SEQ ID NO:
- 4), a LC-CDR2 comprising RASNLES (SEQ ID NO:
- 5), and a LC-CDR3 comprising QQSKEDPYT (SEQ ID NO:
- 6).
7-9. (canceled)
12-14. (canceled)
Dependencies are inferred from the claim text.